



Amikacin [HRP] (DAG1018)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	Amikacin, HRP conjugate
Antigen Description	Amikacin is most often used for treating severe, hospital-acquired infections with multidrug resistant Gram negative bacteria such as <i>Pseudomonas aeruginosa</i> , <i>Acinetobacter</i> , and <i>Enterobacter</i> . <i>Serratia marcescens</i> and <i>Providencia stuartii</i> are also included in the spectrum. Amikacin can also be used to treat non tubercular mycobacterial infections and tuberculosis (if caused by sensitive strains) when first line drugs fail to control the infection. Amikacin may be combined with a beta-lactam antibiotic for empiric therapy for people with neutropenia and fever. Liposomal amikacin for inhalation is currently in late stage clinical trials for the treatment of respiratory diseases, such as cystic fibrosis, <i>Pseudomonas aeruginosa</i> , non tubercular mycobacterial infections and bronchiectasis.
Nature	Synthetic
Expression System	N/A
Species	N/A
Conjugate	HRP
Procedure	None
Format	Concentrate
Size	0.5 mL
Preservative	None
Storage	2-8°C short term, -20°C long term
Warnings	PLEASE note that this product is intended for research use only; not for diagnostic or clinical use.

BACKGROUND

Introduction Amikacin is an aminoglycoside antibiotic most often used for treating severe, nosocomial (hospital acquired) infections with multidrug resistant Gram negative bacteria. Amikacin works by

binding to the bacterial 30S ribosomal subunit, causing misreading of mRNA and leaving the bacterium unable to synthesize proteins vital to its growth.

Keywords

Akacin; Akim; Amicacin; Amicasil; Amiglyde-V; Amikacin Sulfate; Amikacina; amikacine; Amikacinum; Amikavet; Amikin; Arikace; Briclin;
